192 related articles for article (PubMed ID: 31895700)
21. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
[No Abstract] [Full Text] [Related]
22. Targeting the
Amaya ML; Pollyea DA
Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
[TBL] [Abstract][Full Text] [Related]
23. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
[TBL] [Abstract][Full Text] [Related]
24. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
[TBL] [Abstract][Full Text] [Related]
25.
Tong Z; Yerramilli U; Yao S; Young JD; Hoffmann M; Surapaneni S
Xenobiotica; 2019 Oct; 49(10):1229-1236. PubMed ID: 30394160
[TBL] [Abstract][Full Text] [Related]
26. IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
Gu Y; Yang R; Yang Y; Zhao Y; Wakeham A; Li WY; Tseng A; Leca J; Berger T; Saunders M; Fortin J; Gao X; Yuan Y; Xiao L; Zhang F; Zhang L; Gao G; Zhou W; Wang Z; Mak TW; Ye J
Blood; 2021 Feb; 137(7):945-958. PubMed ID: 33254233
[TBL] [Abstract][Full Text] [Related]
27. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
28. Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.
Thomas D; Majeti R
Cancer Discov; 2017 May; 7(5):459-461. PubMed ID: 28461409
[TBL] [Abstract][Full Text] [Related]
29. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
30. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
[TBL] [Abstract][Full Text] [Related]
32. Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations.
Galeotti J; Coombs CC
Br J Haematol; 2019 Feb; 184(4):496. PubMed ID: 30334576
[No Abstract] [Full Text] [Related]
33. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
Molenaar RJ; Wilmink JW
J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233
[TBL] [Abstract][Full Text] [Related]
34. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
35. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W; Kovacsovics T; Blum WG; Schiller GJ; Olin RL; Foran JM; Litzow M; Lin T; Patel P; Foster MC; Boyiadzis M; Collins RH; Chervin J; Shoben A; Vergilio JA; Heerema NA; Rosenberg L; Chen TL; Yocum AO; Druggan F; Marcus S; Stefanos M; Druker BJ; Mims AS; Borate U; Burd A; Byrd JC; Levine RL; Stein EM
Blood Adv; 2024 Jan; 8(2):429-440. PubMed ID: 37871309
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, AML activity and molecular modeling of novel IDH2 inhibitors.
Jin R; Tang T; Zhou S; Tang Y; Guo H; Wang Y; Nie F
Bioorg Chem; 2023 Jan; 130():106225. PubMed ID: 36335650
[TBL] [Abstract][Full Text] [Related]
37. Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Roboz GJ
Clin Adv Hematol Oncol; 2018 May; 16(5):322-325. PubMed ID: 29851927
[No Abstract] [Full Text] [Related]
38. Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
Klink AJ; Gajra A; Knoth RL; Marshall L; Hou Y; McBride A; Copher R
Leuk Res; 2022 Nov; 122():106946. PubMed ID: 36108427
[TBL] [Abstract][Full Text] [Related]
39. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
40. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton S; Montesinos P; Schuh AC; Papayannidis C; Vyas P; Wei AH; Ommen H; Semochkin S; Kim HJ; Larson RA; Koprivnikar J; Frankfurt O; Thol F; Chromik J; Byrne J; Pigneux A; Thomas X; Salamero O; Vidriales MB; Doronin V; Döhner H; Fathi AT; Laille E; Yu X; Hasan M; Martin-Regueira P; DiNardo CD
Blood; 2023 Jan; 141(2):156-167. PubMed ID: 35714312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
